Overview

Study of FG-4592 in Subjects With End-Stage Renal Disease Receiving Maintenance Hemodialysis

Status:
Completed
Trial end date:
2013-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of FG-4592 in maintaining and/or correcting hemoglobin (Hb) given to subjects with End Stage Renal Disease(ESRD)on maintenance hemodialysis
Phase:
Phase 2
Details
Lead Sponsor:
FibroGen
Treatments:
Epoetin Alfa